Consortium

A focused partnership, built for translation

REVOLV brings together the pioneers of light-based tissue printing with the expertise needed to bring the technology to market.

01

01

Leader in translating light-based tissue printing into commercial platforms. Core technology developer in REVOLV, advancing the platform toward industrial-grade workflows.

Creator of the Tomolite platform—the world's first commercially available volumetric bioprinter—and its Apparite control software, developed from research originating at EPFL.

02

02

Originators of light-based tissue-printing research underpinning REVOLV. Scientific and biological validation partner.

Home to the Utrecht Biofabrication Center and the GMP/ATMP-ready Innovation Center for Advanced Therapies; led by Dr. Riccardo Levato, ERC laureate and Board member of the International Society for Biofabrication.

03

03

Experienced SME in impact creation. Leads communication, stakeholder engagement and dissemination.

Building on Horizon Europe

Enlight —> REVOLV

Enlight —> REVOLV

Enlight —> REVOLV

REVOLV builds directly on ENLIGHT, the Horizon Europe project that first demonstrated centimeter-scale, light-shaped living tissue constructs—validated in a pancreas organoid model.

Partner with us

REVOLV homepage

Reliable animal-free and high-throughput volumetric bioprinting of functional 3D assayS

Building on Horizon Europe / ENLIGHT

European Innovation Council: Funded by the European Union

Funded by the European Union under Grant Agreement 101286165. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.